Nadroparin for Pregnant Women With Thrombophilia

Phase 3, randomised, open-label trial of nadroparin in thrombophilia (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Composite endpoint of pregnancy-associated thrombosis, pregnancy-associated thromboembolism, early miscarriage, late miscarriage, preeclampsia, and intrauterine growth retardation at 10.5 months. Status: unknown.